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1. Introduction 
[18F]FDG-PET, a non-invasive metabolic imaging technique, is based on the regional 
distribution of fluorine-18-fluorodeoxyglucose ([18F]FDG) reflecting increased glucose 
consumption of tissues. This technique has become increasingly important over the years in 
the management of patients with malignancies, as many malignant tumors show an 
enhanced glucose metabolism1. [18F]FDG uptake in infections and other inflammatory 
changes seen during oncologic imaging showed indications for the versatility of [18F]FDG-
PET. Activated leukocytes also overexpress glucose transporters and avidly accumulate 
glucose and [18F]FDG 2,3, providing an important rationale for its use in vasculitis. 
Remarkable images of patients with active vasculitis have been generated through [18F]FDG-
PET scans4-12. Such images demonstrate the potential of [18F]FDG-PET for a variety of 
applications which implies that it may also be useful in the future for the routine evaluation 
of patients with several forms of vasculitis, particularly for large vessel vasculitis. 
The family of vasculitides is categorized with reference to the size of vessels involved into 
large, medium, and small vessel vasculitis (Table 1). Of interest with respect to [18F]FDG-
PET imaging is the group of large vessel vasculitides (giant cell arteritis and Takayasu’s 
arteritis), other causes of aortitis and potentially also chronic periaortitis. Patients of both of 
these diseases regularly present a set of non-specific symptoms and laboratory tests which 
make their diagnosis and follow-up quite challenging. Consequently, patients may receive 
delays or even unsuccessful diagnostic work-up regarding their condition. The use of 
whole-body scanning via [18F]FDG-PET may provide a sensitive metabolic imaging 
modality that could lead to a more successful and shorter diagnostic workup. 
The total amount of available data on [18F]FDG-PET in large vessel vasculitis is however still 
limited (Table 2). In addition, no standardized guidelines are in place for the placement of 
[18F]FDG-PET imaging in the sequence of the diagnostic workup, its performance, 
interpretation and description. This chapter summarizes current clinical data in order to 
assist nuclear medicine and rheumatology practitioners in recommending, performing and 
interpreting the results of [18F]FDG-PET in patients with suspected large vessel vasculitis. 
2. Giant cell arteritis 
Giant cell arteritis was first described by Hutchinson in 1890 as a granulomatous vasculitis 
of large and medium sized arteries 13. Giant cell arteritis usually affects the cranial branches 
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of the arteries originating from the aortic arch, particularly the superficial temporal artery; 
however, involvement of the entire aorta and of its main branches also occurs in about 15% 
14. Giant cell arteritis is common in the Caucasian population, with an incidence of about 18 
per 100,000 over 50 years of age 15-17and affects women twice as often as men 15-17. Autopsy 
studies however suggest that it may be much more common than is clinically apparent 18.  
 
Size of 
vessels 
Type of vasculitis Classification Criteria* 
L
ar
ge
 
Giant cell arteritis Age at onset of disease ≥50 yr 
New headache 
Temporal artery abnormality 
Elevated erythrocyte sedimentation rate 
Abnormal findings on biopsy of temporal artery 
 
Takayasu’s arteritis Age at onset of disease ≤40 yr 
Claudication of an extremity 
Decreased brachial artery pulse 
Difference in systolic blood pressure between arms 
A bruit over the subclavian arteries or the aorta 
Narrowing or occlusion of the entire aorta at 
angiography 
M
ed
iu
m
 Peri-arteritis nodosa 
 
Kawasaki’s arteritis 
Primary CNS vasculitis 
Buerger’s disease 
Sm
al
l 
Wegener’s disease 
Churg-Strauss syndrome 
Microscopic polyangiitis 
Henoch-Schonlein purpura 
Essential cryoglobulinaemic 
vasculitis 
Cutaneous leukocytoclastic 
angiitis 
*Diagnosis of giant cell arteritis: at least 3/5 criteria; Sensitivity =93.5%, Specificity =90.5% 
*Diagnosis of Takayasu’s arteritis: at least 3/6 criteria; Sensitivity =91.2%, Specificity =97.8% 
Table 1. Classification of vasculitis 
Currently, the etiology of giant cell arteritis still remains unknown. Classic histological 
pictures of giant cell arteritis show granulomatous inflammation wherein giant cells are 
usually located at the connection between the intima and media. However, panarteritides 
with mixed-cell inflammatory infiltrates of lymphomononuclear cells, occasional 
neutrophils and eosinophils, but without giant cells are also found 19. The focal arteritic 
lesions cause ischemia which subsequently leads to the sudden or gradual onset of 
symptoms and a variety of systemic manifestations. A variety of systemic symptoms may be 
present 20,21, and include myalgia, neck pain, scalp tenderness, jaw claudication, fever, 
www.intechopen.com
 
FDG-PET in Large Vessel Vasculitis 
 
59 
tenderness of the temporal arteries, transient ischemic attacks, general malaise, fatigue, 
anorexia, weight loss, depression, and night sweats 20,22,23. Headache is probably the most 
frequent symptom which occurs in two thirds of patients 21. 
 
Authors Year 
Takayasu 
arteritis 
(number of 
patients) 
Giant cell arteritis 
(number of patients)
Follow-up 
PETs 
Reference 
Blockmans et al. 1999 - 11* - 63 
Blockmans et al. 2000 - 25* - 64 
Belhocine et al. 2002 - 3 3 65 
Meller et al. 2003 5 - - 52 
Meller et al. 2003 1 14 7 48 
Bleeker-Rovers et al. 2003 1 7* 1 45 
Webb et al. 2004 18 - 8 44 
Brodman et al. 2004 - 22 - 46 
Moosig et al. 2004 - 12* 8 47 
Andrews et al. 2004 6 - 6 43 
Scheel et al. 2004 - 8 8 53 
Kobayashi et al. 2005 14 - 7 50 
Walter et al. 2005 6 20 4 49 
Blockmans et al. 2006 - 35* 22 66 
Blockmans et al. 2008 - 46 25 67 
Both et al. 2008 - 25 9 68 
Hautzel et al. 2008 - 18 - 69 
Henes et al. 2008 3 10 - 70 
Janssen et al. 2008 - 11 - 71 
Arnaud et al. 2009 28 - 8 72 
Lee et al. 2009 32 - - 73 
Vista et al. 2010 4 - - 74 
Lehmann et al. 2011 3 17 - 75 
*Giant cell arteritis and polymyalgia rheumatica patients 
Table 2. Clinical studies on PET in the detection of large vessel inflammation: the present 
literature 
3. Takayasu's arteritis 
Takayasu's arteritis is named after Mikito Takayasu, who in 1908 had reported the 
peculiar wreath-like arteriovenous anastomoses around the papillae in a young woman 
with pulseless disease 24. This large vessel vasculitis primarily affects the aorta, its main 
branches, and the coronary and pulmonary arteries. The incidence rate of the disease is 
about 2 per 1,000,000 with its onset at a mean of 35 years of age 25-27. Takayasu's arteritis 
occurs worldwide, although it is considered to be more common in the Orient 28 and is 10 
times more prevalent in females than in males. The etiology of Takayasu's arteritis also 
remains unresolved, while the clinical course includes both an early and a late phase. 
Pathology studies in the early phase reveal granulomatous or diffuse productive 
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inflammation in the media and adventitia, with secondary thickening of the intima and 
occasional perivascular inflammation 29. In the clinic, it is commonly the setting of fever of 
unknown origin with non-specific systemic symptoms. Contrary to the early phase, 
pathology studies in the late phase show marked thinning of the media, with disruption 
of elastic fibers, fibrotic thickening of the adventitia, and marked intimal proliferation29. 
The resulting variable ischemic symptoms secondary to arterial stenosis, occlusion, or 
arterial dilatation and aneurysmal formation cause various clinical conditions, such as 
arm claudication, decreased arterial pulses, carotodynia, visual loss, stroke, aortic 
regurgitation and arterial hypertension30. Topological classification of Takayasu's arteritis 
is based on the vascular provinces that are affected 31, with either affection of the branches 
of the aortic arch (Type I), the ascending aorta, aortic arch and its branches (Type IIa), the 
ascending aorta, aortic arch and its branches and the thoracic descending aorta (Type IIb), 
the thoracic descending aorta, abdominal aorta, and/or renal arteries (Type III),  
the abdominal aorta and/or renal arteries (Type IV) or combined features of types IIb  
and IV. 
4. Diagnostic work-up in large vessel vasculitis 
Giant cell arteritis and Takayasu’s arteritis are both usually present with a wide clinical 
spectrum with no specific laboratory finding. The American College of Rheumatology has 
established a set of clinical, radiological and histological criteria to classify cases of biopsy-
proven arteritis (Table 1) 32,33. The presence of at least three of the described criteria is 
required for classifying a patient as having either Takayasu’s arteritis or giant cell arteritis. 
These criteria provide a sensitivity of 93.5% with a specificity of 90.5% for diagnosing giant 
cell arteritis and a sensitivity of 91.2% with a specificity of 97.8% for diagnosing Takayasu’s 
arteritis in biopsy-positive patients.  
Although these criteria were originally designed for research purposes to help distinguish 
between different types of vasculitis; they are in clinical practice also frequently used for 
diagnosing an individual patient 34. Nevertheless, the fact that frequent symptoms of giant 
cell arteritis such as jaw claudication, diplopia, neck pain, and elevated C-reactive protein 
are not included in the criteria, limits their widespread clinical application. Criteria that are 
included, such as headache and scalp tenderness can also be due to various other diseases. 
A normal erythrocyte sedimentation rate does not rule out giant cell arteritis, as it has been 
found in up to 30% of patients with biopsy-proven giant cell arteritis 35,36. Furthermore, 
several patients with giant cell arteritis do only display nonspecific symptoms that does not 
apply to any set of criteria. Systemic giant cell arteritis symptoms such as fever, anorexia, 
weight loss and malaise may focus the diagnostic work-up towards a suspected malignancy, 
especially in older patients 37. 
Frequent clinical features of Takayasu’s arteritis such as fever, postural dizziness, 
arthralgias, weight loss, headache, hypertension, elevated erythrocytes sedimentation rate 
and anemia were also not included in the classification criteria of the American College of 
Rheumatology. In contrast, angiographic findings and non-congruent blood pressure 
measurements between both arms are included as part of the diagnostic criteria although 
they may be false negative in early vasculitis 38,39 , or when the arteritis is restricted to the 
abdominal aorta, its branches, or to the pulmonary artery. 
The wide clinical spectrum and the diagnostic limitations of giant cell arteritis and 
Takayasu’s arteritis frequently cause delay in their diagnosis and subsequent treatment.  
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5. [
18
F]FDG-PET and [
18
F]FDG-PET/CT 
[18F]FDG-PET is an operator-independent, non-invasive imaging modality which examines 
the regional distribution of fluorine-18-fluorodeoxyglucose. Deoxyglucose is labeled with 
the positron emitting radionuclide, 18Fluorine, and is intravenously administered to 
patients. [18F]FDG initially distributes in proportion to the perfusion of the organs, where it 
follows the same route of uptake as glucose. After entering cells through specific carriers, 
[18F]FDG is phosphorylated to [18F]FDG-6-phosphate, trapped intracellularly, but not 
metabolized further. The emitted positrons can be detected by a scanner and are displayed 
as a bright signal in the [18F]FDG-PET scan, reflecting an increased glucose requirement. 
Heightened glucose metabolism is a property of many malignancies, a fact which has 
fostered the use of  [18F]FDG-PET studies in the staging and follow-up in various types of 
cancers 1.  
Modern PET-CT scanners combine PET scanners with a computed tomography scanner in a 
single gantry system. With these scanners, images are taken sequentially with both devices 
in the same session and the reading can be done with the single co-registered image. As a 
consequence, the functional image obtained by PET, can be correlated more precisely with 
the anatomic structures. PET/CT has shown an incremental diagnostic value over CT and 
PET alone and there is emerging evidence of a substantial impact of PET/CT imaging on 
patient management 40. 
6. [
18
F]FDG-PET scanning protocols for large vessel vasculitis 
The American and the European Association of Nuclear Medicine have both established 
procedure guidelines for tumor imaging with [18F]FDG-PET 41,42. The guidelines of the 
American Association of Nuclear Medicine from 1998 recommend fasting at least 4 hours 
prior to the scan. Low blood glucose levels are recommended, the injected activity should 
total 350 to 750 MBq [18F]FDG, and image acquisition should start 30 to 40 minutes after 
injection. In contrast, the guidelines of the European Association of Nuclear Medicine from 
the year 2003 advocate fasting at least 6 hours prior to the scan. Blood glucose level should 
not exceed 130mg/dl, the injected [18F]FDG activity should be 6 MBq/kg body weight, and 
acquisition should be started 60 minutes after injection.  
Both professional associations however, have not established guidelines for the PET imaging 
of inflammation and consequently, the present studies (Table 2) have used several different 
protocols. Pre-scan fasting intervals of 4 hours 43,44, 6 hours 45-47, and overnight fasts 48-50 
were applied. Body-weight adapted protocols for the applied [18F]FDG dose with 5 49, 6 50 or 
6.5 MBq 46,51 [18F]FDG per kilogram bodyweight were used. However, fixed doses of 296 
MBq 52, 370 MBq 48, and 450 MBq 47 were also employed. To accelerate renal [18F]FDG 
elimination, one group also routinely administered additional furosemide 45. Most studies 
on [18F]FDG-PET in large vessel vasculitis did not restrict scanning by maximal glucose 
levels and only three studies tolerated maximum serum glucose levels of 100mg/dl 48,52 and 
180mg/dl 49. Large differences in the time interval between [18F]FDG application and image 
acquisition were also shown as [18F]FDG-uptake periods of 45 minutes 49,50, 60 minutes 
45,46,48,51,52, or 90 minutes 43,44,47 were reported. Dedicated PET scanners with full-ring 
detectors were generally used; nevertheless, hybrid cameras have also been successfully 
employed 48,52,53. Reports on the use of combined [18F]FDG-PET-CT scanners in large vessel 
vasculitis are available 50,54,55. 
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The average radiation dose from the [18F]FDG-PET scan is 7mSv, the average dose from the 
CT scan is 18mSv. The CT dose, however, can be lowered by the use of low-dose acquisition 
protocols. 
This summary indicates that despite a lack of standardization, [18F]FDG-PET is a reliable 
imaging modality of large vessel vasculitis. 
7. [
18
F]FDG-PET and atherosclerosis 
The accumulation of glucose analogues has not only been demonstrated in vasculitic 
vessels, but also in atherosclerotic plaques (Figure 1) 56. Consequently, a modest large vessel 
[18F]FDG accumulation at the level of the major vessels occurs in about 50% of all PET-scans, 
with increased prevalence in older people 57. This vascular uptake might be explained by 
smooth muscle metabolism in the media, subendothelial smooth muscle proliferation from 
senescence, and the presence of macrophages within the atherosclerotic plaque. Therefore, 
vascular uptake found in the [18F]FDG-PET scan is not specific for vasculitis. 
 
 
Fig. 1. 71-year-old female patient that underwent FDG-PET/CT to evaluate a suspicious 
lung nodule. Focal FDG uptake was found in the thoracic and abdominal aorta 
corresponding to circumscribed artherosclerotic and aneurysmatic wall changes (arrow; 
from the Institute of Nuclear Medicine, University Hosptial, Bern, CH) 
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Nevertheless, atherosclerotic lesions can be differentiated from vasculitic lesions by  
taking into account the vascular distribution, [18F]FDG uptake pattern, and the intensity of 
the [18F]FDG accumulation. For example, the internal carotid artery demonstrates 
atherosclerotic changes more frequently, while the external carotid artery more often reveals 
inflammatory changes. The uptake pattern of atherosclerotic mediastinal great vessels 
sometimes can be identified as ring-shaped structures, while contrary to this, the uptake 
pattern in the arteries of the abdomen and lower extremities are often linear and continuous 
58. Most discriminatingly, atherosclerotic lesions rarely demonstrate intense uptake of  
FDG 48,49. 
To distinguish vasculitis from atherosclerosis, a visual scoring of vascular [18F]FDG-uptake 
compared to the liver [18F]FDG-accumulation has been established. Three grades of large 
vessel [18F]FDG-uptake are differentiated (Figure 2): a) Grade I: uptake present but lower 
than liver uptake, b) Grade II: similar to liver uptake, and c) Grade III: uptake higher than 
liver uptake. Proposed by Meller et al. 48, this scale was subsequently validated to represent 
the severity of inflammation 49.  
 
B CA
 
Fig. 2. The visual arteritis score as proposed by Meller et al. 48. The severity of large vessel 
[18F]FDG-uptake is visually graded: A) Grade 1: uptake present but lower than liver uptake; 
B) Grade 2: similar to liver uptake; C) Grade 3: uptake higher than liver uptake (images 
derived from reference 49). 
So far, this score has been employed in two reference collectives without clinical symptoms 
or laboratory signs of large vessel inflammation in order to determine the uptake in non-
vasculitic vessels 48,49. Grade I vessel uptake was frequently found in the thoracic part of the 
aorta which was most likely due to atherosclerosis. Accordingly, only Grade II or III 
[18F]FDG-uptake in the thoracic aorta and any visible uptake in other segments should 
routinely be judged as active large vessel inflammation. In this manner, the majority of 
lesions can be ruled out as due to atherosclerosis. On the other hand, computed 
quantification of [18F]FDG-uptake using the [18F]FDG standardized uptake value (SUV) has not 
shown to be useful in discriminating atherosclerosis from vasculitis yet. 
8. [
18
F]FDG-PET for diagnosing giant cell arteritis 
The diagnosis of giant cell arteritis is currently based mainly on clinical evaluation, 
laboratory results, and temporal biopsy, but a gold standard is lacking. Despite recent 
advances, no imaging modality has been included in the American College of 
Rheumatology diagnostic criteria for giant cell arteritis (Table 1). Nevertheless, [18F]FDG-
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PET has indicated its usefulness clinically for a number of studies through better evidence, 
as compared to Takayasu’s arteritis, due to the higher frequency of the disease (Table 2). 
The uptake pattern in large vessels affected by giant cell arteritis was linear, continuous, and 
was predominantly of Grade II. The thoracic vessels were most frequently affected, followed 
by the abdominal vessels 48,49. In the published studies, the ability of [18F]FDG-PET to detect 
large vessel inflammation differed considerably. In studies employing patients with 
polymyalgia rheumatica and giant cell arteritis, sensitivities between 56% and 100% were 
reported 45,46,51,53, with a specificity between 77% and 98% 51. The large differences seen 
between the studies can partially be explained by dissimilar disease activity; as suggested by 
one study demonstrating that the sensitivity depends on the degree of inflammation (Figure 
4). C-reactive protein has shown to be a better predictor for the sensitivity of [18F]FDG-PET 
in giant cell arteritis than the erythrocyte sedimentation rate 49. 
Studies employing [18F]FDG-PET and Magnetic Resonance Imaging (MRI) revealed 
comparable sensitivities for both methods. [18F]FDG-PET may have the advantage that it 
simultaneously identifies more affected vessels 48,53, possibly reflecting the fact that 
metabolic changes normally precede morphologic changes in giant cell arteritis. 
Additionally, [18F]FDG-PET might also allow new insights into the pathology of giant cell 
arteritis and polymyalgia rheumatica. A study demonstrated inflammation of the aorta or its 
major branches in 92% of patients with polymyalgia rheumatica. Tracer uptake was strongly 
correlated with the erythrocyte sedimentation rate and the C-reactive protein. These data 
underline that polymyalgia rheumatica frequently may be accompanied by subclinical 
vasculitis 47. 
[18F]FDG-PET also offers the possibility of whole-body screening in one procedure which 
may become helpful in the follow-up of patients with giant cell arteritis. The results of 
computed quantification of vascular [18F]FDG accumulation correlate well and better than 
Magnetic Resonance Imaging with the clinical course also at longitudinal follow up 47,48. 
The value of [18F]FDG-PET for diagnosing temporal arteritis has however been questioned 
in a study of 22 patients, 17 of which had involvement of the temporal arteries which was 
not detected by [18F]FDG-PET 46. The high [18F]FDG uptake of the brain and the small 
diameter of the temporal arteries limited its sensitivity in the detection of cranial vessel 
involvement with the whole-body PET technique used. Newer generation PET/CT scanners 
offer an image resolution corresponding to a three-fold improvement compared to the 
technology used in the aforementioned study (2mm vs. 7mm), potentially allowing to image 
even smaller arteries as the temporal arteries. Further clinical studies must are warranted to 
clarify the potential role of PET in the non-invasive work-up of temporal vasculitis. 
9. [
18
F]FDG-PET for diagnosing Takayasu’s arteritis 
The diagnosis of Takayasu’s arteritis frequently integrates imaging and angiographic  
(Table 1). However, angiographic alterations usually occur in the late phase of Takayasu’s 
arteritis while metabolic changes are already present in the early phases. The data on the use 
of [18F]FDG-PET in Takayasu’s arteritis are less robust compared to those in giant cell 
arteritis (Table 2), accounting for the different prevalences of both vasculitides.  
During the early phase of Takayasu’s arteritis, the [18F]FDG uptake pattern is linear and 
continuous (Figure 3A), while in the late phase the pattern can become patchier rather than 
continuous but still remains in a linear distribution 44.  Three studies reported sensitivities of 
[18F]FDG-PET between 83% and 100% 43,44,52, which is comparable to  Magnetic Resonance 
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Imaging. Additionally, metabolic imaging using [18F]FDG-PET for Takayasu’s arteritis has 
identified more affected vascular regions than morphologic imaging using Magnetic 
Resonance Imaging 52. However, unlike Magnetic Resonance Imaging, [18F]FDG-PET does 
not give any information about the wall structure or the lumen of affected vessels. 
Similarly to giant cell arteritis, there is a clear correlation between the activity of vessel 
inflammation and the sensitivity of [18F]FDG-PET. [18F]FDG-PET positive patients have 
shown significantly higher erythrocyte sedimentation rates and C-reactive protein levels as 
compared to [18F]FDG-PET negative patients, with the C-reactive protein being the superior 
marker 44.  
Follow-ups in Takayasu’s arteritis only based on clinical symptoms alone have shown to be 
of limited accuracy. In a previous report, biopsies showed active inflammation in 44% of 
patients thought to be in clinical remission 59. However, [18F]FDG-PET is able to detect more 
sites than just those that were clinically active 44. This makes [18F]FDG-PET a promising 
candidate to be regularly employed in the follow-up of Takayasu’s arteritis (Figure 3) due 
its high sensitivity and the good correlation with the outcome 43,44,49. 
 
BA
 
Fig. 3. A) [18F]FDG-PET of a patient with Takayasu’s arteritis with markedly abnormal 
uptake of [18F]FDG in the aortic arch and carotide arteries (arrows). B) [18F]FDG-PET scan of 
the same patient in clinical remission after treatment with prednisone and intravenous 
cyclophosphamide (from reference 43) 
10. [
18
F]FDG-PET-CT in large vessel vasculitis 
The combination of [18F]FDG-PET scanners with Computed Tomography (CT) has gained 
importance in the management of patients with malignancies 60-62 by allowing the 
integration of morphologic and metabolic information for detection, staging, and therapy 
control. Rapidly increasing availability of [18F]FDG-PET-CT scanners are also opening new 
opportunities for its application in rheumatology by allowing the investigation of both 
morphologic and metabolic activity while significantly improving the localization of 
affected vessels. Two case reports have already indicated the value of [18F]FDG-PET-CT 
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Fig. 4. Sensitivity of Large Vessel Vasculitis [18F]FDG-PET as a function of C-reactive protein 
(CRP)levels and erythrocyte sedimentation rate (ES§) , respectively. High sensitivity for 
detection of large vessel vasculitis is reached at high CRP and ESR levels (from reference 49). 
 
 
Fig. 5. 52 year-old female patient with clinical suspision of a large vessel vasculitis. The 
FDG-PET/CT shows intense tracer uptake along the aortic arch, the supraaortic branches 
and the supraclavicular arteries. There is also uptake along the abdominal aorta and femoral 
arteries and branches. 
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Fig. 6. FDG-PET/CT of a 67-year-old male patient with recent loss of weight and continious 
deterioration of his general condition. The PET/CT performed did not support the clinical 
suspicion of a malignant tumor but showed intense vessel uptake (A). Additional high-
resolution PET images of the chest and neck illustrate the ability of state-of-the-art PET 
machines to visualize circumscribed wall inflammation even in medium sized arteries as the 
carotic sinus and the vessel wall of the aortic arch (B) 
scanners in large vessel vasculitis 53,54 and one clinical trial has investigated its value in 14 
patients 50. The co-registered CT scan was most useful for the anatomic identification of 
vascular [18F]FDG-uptake, especially in case of rather moderate [18F]FDG-accumulation. 
Furthermore, the anatomic identification of mediastinal [18F]FDG uptake, particularly in the 
pulmonary arteries was significantly improved (Figure 5). The coregistered CT scan allows 
for a sensitive detection of calcified plaques to discriminate vasculitis from inflammatory 
arteriosclerotic changes.  
11. Conclusions 
In conclusion, whole-body imaging with [18F]FDG-PET is highly effective in assessing the 
extent of giant cell arteritis and Takayasu’s arteritis, respectively. 
[18F]FDG-PET has shown to have identified more affected vascular regions than 
morphologic imaging with Magnetic Resonance Imaging in both diseases. 
A unique feature and strength of FDG-PET is the opportunity to monitor disease activity 
non-invasively. In contrast to other imaging modalities PET allows for an immediate 
assessment of response to anti-inflammatory treatment and is suitable to guide therapy. 
Recent developments in PET technology such as integrated PET/CT machines and 
increased image resolution of the PET submodality imply significant improvements for 
vaculitis imaging with FDG. 
Further studies are warranted to evaluate the diagnostic benefit of these newer technical 
developments. 
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[18F]FDG-PET has the clear potential to develop into a valuable tool in the diagnostic work-
up of both giant cell arteritis and Takayasu’s arteritis, and may become a first-line 
investigation technique for non-invasive therapy monitoring. However, consensus 
regarding the imaging procedures as well as further clinical evidence is urgently needed. 
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